Kdigo guidelines steroid resistant nephrotic syndrome

Endocrine Treatment of Transsexual Persons
Last updated :         2009
Published :             J Clin Endocrinol Metab   2009; 94:3132–3154
Sponsor:               Endocrine Society, European Society of Endocrinology, European Society for Paediatric Endocrinology, Lawson Wilkins Pediatric Endocrine Society, and World Professional Association for Transgender Health
Website :              http://-/guidelines/Current-Clinical-Practice-

Corticosteroids are often used in the treatment of NS despite an absence of supporting data. In recent years, corticosteroids and other immunosuppressive treatments have been investigated for use in NS ( Table 4 ) . 15 A Cochrane review showed that combining an alkylating agent with a corticosteroid has short- and long-term benefits for membranous nephropathy in adults with NS. 15 In general, immunosuppressive treatment has no proven benefit for most adults with idiopathic NS, and the potential risks may outweigh any benefits. The role of such treatment and specific treatment decisions, such as type and duration of therapy, depend on clinical factors and potentially on the histologic diagnosis identified on biopsy. If NS is steroid-resistant or does not improve, other immunosuppressive treatments should be considered in cooperation with a nephrologist. Immunosuppressive therapy for NS secondary to systemic lupus erythematosus is highly effective and supported by multiple studies, and may lead to partial or complete remission in patients with minimal change disease or primary focal segmental glomerulosclerosis.

Introduction: The UEMS and ERA-EDTA Alliance
Jorge B. Cannata-Andía , Oviedo, Spain
The current status of European Nephrology Education
Talia Weinstein , Tel Aviv, Israel
Recruiting high calibre fellows into Nephrology:
Challenges and Solutions
Nadine Vogelsang , Münster, Germany
Progressing training harmonisation.
The “European Certifi cate in Nephrology”
David Lappin , Galway, Ireland
Knowledge-based examination in Nephrology:
The UK experience
Jonathan G. Fox , Glasgow, United Kingdom
Mapping future progress. Panel and audience general discussion lead by Anibal Ferreira , Lisbon, Portugal and Itzchak Slotki , Jerusalem, Israel

Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.

Kdigo guidelines steroid resistant nephrotic syndrome

kdigo guidelines steroid resistant nephrotic syndrome

Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.

Media:

kdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndrome

http://buy-steroids.org